Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Chemotherapy for Advanced Small Cell Lung Cancer
NCT03547804Phase 2Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by The First Hospital of Jilin University. Started May 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03547804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547804.